TPST-2206 (Tempest Therapeutics)

TPST-2206 is an oral small-molecule therapeutic candidate being developed by Tempest Therapeutics for the treatment of hepatocellular carcinoma (HCC). While specific details regarding its biological target and mechanism of action have not been fully disclosed in early pipeline disclosures, it is part of a portfolio of oral therapeutics designed to treat cancer through direct tumor-targeted killing, immune system activation, or a combination of both. As of early 2026, the program is in the preclinical stage of development. Note: Recent strategic shifts at Tempest Therapeutics involving the acquisition of cell therapy assets have introduced a CAR-T program with the same code name (TPST-2206) for renal cell carcinoma, but the original small-molecule program was identified for HCC.